Focusing on genetic and phenotypic heterogeneity in AML, Dr. Elli Papaemmanuil (The Memorial Sloan Kettering Cancer Center in New York, USA) presented the revised genomic classification for AML based on cancer gene driver and passenger mutations, and reported the emergence of three novel heterogeneous genomic categories added to the pre-existing classifications: i) chromatin-spliceosome; ii) p53-aneuploidies; and iii) IDH2R172 mutations. This evidence concerns the gene TP53 and cancer.